Close this search box.


Dermo-cosmetics is constantly evolving and requires studies to back up new claims. Companies in this sector are demanding in terms of quality and speed of delivery. At GAIKER, we have adapted our knowledge of the pharmaceutical sector to provide a high quality scientific service to the dermo-cosmetic industry, where rigorous scientific studies that demonstrate the properties of active ingredients and end products are increasingly valued. Brand image and differentiation from competitors, as well as customer trust, depend on these studies to a large extent.


Our dermo-cosmetic solutions are mainly based on the development of in vitro methods and models to better understand the action mechanism of different active ingredients and end products. Our models range from in tube enzyme tests to testing on volunteers, as well as testing in 3D models (reconstituted epidermis, corneal, nasal or vaginal epithelium) and ex vivo tests on human skin. In human skin models, we specialise in the development of models of different pathologies or associated problems, such as aged, photo-aged, inflamed, ulcerated, burned and irritated skin, dermatitis, etc.

In addition to efficacy studies, GAIKER uses its knowledge of in vitro safety tests in accordance with regulations, to perform cosmetic safety studies prior to placing these products on the market. Animal testing of cosmetic products is banned in Europe.

Major Projects


The main aim is to develop a new generation of plant-based skin treatments with applications in the pharmaceutical and cosmetic industry. Active ingredients rich in anti-quormones will be designed to disarm bacteria by hacking into their communication systems, in the same way plants do. As a result, skin pathologies will be treated and prevented in a way that is sensitive to the skin's ecosystem.


Obtaining a line of products with effective phyto-factors (PF) for hygiene and hydration in the treatment of atopic dermatitis, which does not alter the properties of the skin or its microbiota, and does not affect the patient's immune system.


The main aim of MOSAIC is to carry out bioprospecting aimed at identifying and characterising (i) new microorganisms (fungi and bacteria) with a high capacity to hydrolyse marine polysaccharides, (ii) new families of enzymes (glycosyl hydrolases and sulfatases) with a high potential value for the biomedical and biotechnological industry, and (iii) new active ingredients for the pharmaceutical industry from processing marine glycans.

Subsidised by the Basque Government


The aim of this project is to obtain biocompounds with improved activity for treating cancer by developing new delivery systems, based on nanoencapsulation technologies, which improve the bioavailability of these compounds in oral and topical formulations.

Subsidised by the Basque Government

No results found.

Would you like to talk to an expert?